Zosano Pharma Corporation
ZSAN
ZSAN was delisted on the 10th of June, 2022.
22 hedge funds and large institutions have $6.3M invested in Zosano Pharma Corporation in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 5 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
15% less funds holding
Funds holding: 26 → 22 (-4)
50% less capital invested
Capital invested by funds: $12.5M → $6.3M (-$6.22M)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$108K |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$79.9K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$50.6K |
| 4 |
VF
Virtu Financial
New York
|
+$33K |
| 5 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$24.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.73M |
| 2 |
Morgan Stanley
New York
|
-$73.3K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$56.5K |
| 4 |
NC
Nexthera Capital
New York
|
-$44.7K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$15K |
ZSAN Hedge Fund Activity: Q3 2017 in Review
22 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Zosano Pharma Corporation (ZSAN) for Q3 2017, worth a combined $6.3M — down 50% from $12.5M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ZSAN and 2 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was CIBC Private Wealth Group, opening a new position worth an estimated $108K. The largest seller was Opaleye Management, exiting entirely with an estimated $1.73M sold.
- 22 institutional investors held Zosano Pharma Corporation (ZSAN) as of Q3 2017, down from 26 in Q2 2017.
- Funds reported $6.3M of Zosano Pharma Corporation stock for Q3 2017, down 50% quarter-over-quarter.
- 2 funds opened new Zosano Pharma Corporation positions in Q3 2017 and 5 closed out, a net change of -3 holders.
- The largest Zosano Pharma Corporation buyer in Q3 2017 was CIBC Private Wealth Group, an estimated $108K added.
- The largest Zosano Pharma Corporation seller in Q3 2017 was Opaleye Management, an estimated $1.73M sold.
Based on aggregated 13F filings for Q3 2017.